Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options

Daniele Veritti,1 Valentina Sarao,1,2 Valentina Soppelsa,1 Paolo Lanzetta1,2 1Department of Medicine - Ophthalmology, University of Udine, Udine, Italy; 2Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, ItalyCorrespondence: Paolo LanzettaDepartment of Medicine - Ophthalmology, University of...

Full description

Bibliographic Details
Main Authors:	Veritti D, Sarao V, Soppelsa V, Lanzetta P
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-01-01
Series:	Clinical Ophthalmology
Subjects:	aflibercept anti-vegf bevacizumab dexamethasone diabetic macular edema ranibizumab
Online Access:	https://www.dovepress.com/managing-diabetic-macular-edema-in-clinical-practice-systematic-review-peer-reviewed-article-OPTH

Similar Items

Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression
by: Daniele Veritti, et al.
Published: (2022-01-01)

Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema
by: Hakan Koc, et al.
Published: (2023-03-01)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016-08-01)

Current approaches to the treatment of diabetic macular edema. A literature review
by: E. V. Bobykin
Published: (2019-04-01)

Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association
by: V. Levent Karabaş, et al.
Published: (2022-06-01)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
by: Yoshihiro Takamura, et al.
Published: (2021-12-01)

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
by: J. M. Ruiz-Moreno, et al.
Published: (2020-09-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Current Treatments of Diabetic Macular Edema
by: Wei-Chun Chan, et al.
Published: (2011-12-01)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01)

Influence of Intravitreal Therapy on Choroidal Thickness in Patients with Diabetic Macular Edema
by: Patricia Udaondo Mirete, et al.
Published: (2023-01-01)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018-01-01)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
by: Alper Halil Bayat, et al.
Published: (2019-12-01)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021-05-01)

Assessment of Anti-VEGFs in Treating Diabetic Macular Edema in Alfaisal Eye Center, Khartoum, Sudan, 2019
by: Ahmedalgabri RHM, et al.
Published: (2022-04-01)

Aflibercept compared with dexamethasone in diabetic macular edema
by: Rodolfo Garretón, et al.
Published: (2021-05-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

Management of Macular Edema Secondary to Branch Retinal Vein Occlusion in an Eye with Prior Vitrectomy and Lensectomy
by: Pankaj Malhotra, et al.
Published: (2014-10-01)

Should we consider pars plana vitrectomy in the primary treatment of diabetic macular edema?
by: Lihteh Wu, et al.
Published: (2017-01-01)

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
by: Bianka Sobolewska, et al.
Published: (2017-06-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema
by: Hossam El Deen Khalil, et al.
Published: (2022-07-01)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
by: Mahmoud Alaa Abouhussein, et al.
Published: (2021-01-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

Aflibercept versus dexamethasone for macular edema secondary to central retinal vein occlusion
by: Rodolfo Garretón, et al.
Published: (2019-12-01)

Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis
by: Xian Wang, et al.
Published: (2022-06-01)

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study
by: Abdullah Özkaya, et al.
Published: (2017-05-01)

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
by: Joel Hanhart, et al.
Published: (2015-02-01)

Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
by: Shinichiro Chujo, et al.
Published: (2020-09-01)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
by: Sławomir Liberski, et al.
Published: (2022-08-01)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
by: Laine I, et al.
Published: (2017-11-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data
by: Dominic Muston, et al.
Published: (2018-12-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

The Safety of Anti-VEGF Treatment, in the Context of the Retinal Nerve Fibre Layer, in Patients with Wet Age-Related Macular Degeneration: A Review
by: Małgorzata Wichrowska, et al.
Published: (2023-09-01)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
by: Mahmut Kaya, et al.
Published: (2023-02-01)

Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy
by: Tessy Xavier, et al.
Published: (2021-01-01)

Primary treatment of diabetic macular edema
by: Tushar M Ranchod, et al.
Published: (2009-02-01)